Abbott, MichaelRyan, MandyHernández, Rodolfo AndrésMcKenzie, LyndaHeidenreich, SebastianHocking, LynneClark, CarolineAnsari, MoradMoore, DavidLampe, AnneMcGowan, RuthBerg, JonathanMiedzybrodzka, Zosia2025-05-302025-05-302025-04Abbott, M, Ryan, M, Hernández, R A, McKenzie, L, Heidenreich, S, Hocking, L, Clark, C, Ansari, M, Moore, D, Lampe, A, McGowan, R, Berg, J & Miedzybrodzka, Z 2025, 'Should Scotland Provide Genome-Wide Sequencing for the Diagnosis of Rare Developmental Disorders? A Cost-Effectiveness Analysis ', European Journal of Health Economics, vol. 26, no. 3, pp. 503-512. https://doi.org/10.1007/s10198-024-01717-81618-7598ORCID: /0000-0003-2619-8230/work/171979689ORCID: /0000-0003-2890-8136/work/175113466https://hdl.handle.net/2164/25530The authors would like to thank the Scottish Genomes Partnership for their support with this work. Specifically, we thank, Christine Bell, Austin Diamond and Jon Warner for their collaboration. We thank Amy Rowlatt, Tessa Coupar, Courtney Elliot, Lorna McLean, Laura Taylor, Resifina Seyara, Florence Richards and Quinn Heppe for collecting the genetic testing data which was used to generate costs. We thank Professor Tim Aitman for his conceptualisation and management of the Scottish Genomes Partnership. We would also like to thank Edinburgh Genomics at the University of Edinburgh for their participation in the SGP project, the current NHS Scotland trio ES service, as well as their contribution to the generation of costs for this study. We also thank the members of our Project Advisory Group: Deborah Marshall, Sarah Wordsworth, Richard Herriot, Natalie Frankish, Sarah Ogilvie and Nicola Williams for providing comments on earlier versions of the cost-effectiveness model. Finally, this work would not be possible without the families, clinicians, nurses, research scientists, laboratory staff and wider members of the Scottish Genomes Partnership and Deciphering Developmental Disorders studies, to whom we give our grateful thanks.10987051engSDG 3 - Good Health and Well-beingCost effectivenessEconomic evaluationGeneticsGenomicsRare conditionsR MedicineEconomics, Econometrics and Finance (miscellaneous)Health PolicySupplementary DataDASRJournal article10.1007/s10198-024-01717-8http://www.scopus.com/inward/record.url?scp=85203355835&partnerID=8YFLogxK263